Publications by authors named "Ching-Chu Lo"

Claim this Profile
E
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan.
Szu-Jen Wang, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Chien-Wei Huang, Wang-Long Chuang

Kaohsiung J Med Sci· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study.
Teng-Yu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Ching-Chu Lo, Wan-Long Chuang

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction Model for Risk of Hepatocellular Carcinoma After Hepatitis C Viral Eradication.
Wei-Fan Hsu, Ching-Chu Lo, Kuo-Chih Tseng, Hsueh-Chou Lai, Chi-Yi Chen

J Hepatocell Carcinoma· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry.
Tyng-Yuan Jang, Chung-Feng Huang, Te-Sheng Chang, Chun-Chi Yang, Ching-Chu Lo, Wang-Long Chuang

J Formos Med Assoc· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry.
Ping-Jen Hu, Pei-Chien Tsai, Chi-Yi Chen, Hsing-Tao Kuo, Chao-Hung Hung, Gin-Ho Lo, Ching-Chu Lo, Wan-Long Chung

Kaohsiung J Med Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study.
Shou-Wu Lee, Sheng-Shun Yang, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Ching-Chu Lo, Wan-Long Chuang

Clin Mol Hepatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH).
Ping-Jen Hu, Ming-Lung Yu, Ming-Yao Chen, Chi-Yi Chen, Hsing-Tao Kuo, Gin-Ho Lo, Ching-Chu Lo, Wan-Long Chung

J Formos Med Assoc· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial.
Young-Suk Lim, Ming-Lung Yu, Jonggi Choi, Chi-Yi Chen, Won-Mook Choi, Ching-Chu Lo

Lancet Gastroenterol Hepatol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.
Szu-Jen Wang, Chung-Feng Huang, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Wang-Long Chuang

Kaohsiung J Med Sci· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-normal and abnormal alanine transaminase levels linked to increased risk of hepatoma following treatment for chronic hepatitis C.
Yen-Chun Chen, Pei-Chien Tsai, Chung-Feng Huang, Chi-Yi Chen, Chao-Hung Hung, Ching Chu Lo, Wan-Long Chuang

J Formos Med Assoc· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program.
Hung-Wei Wang, Yu-Syuan Zeng, Chung-Feng Huang, Chi-Yi Chen, Hsing-Tao Kuo, Ching-Chu Lo, Wan-Long Chuang

J Formos Med Assoc· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.
Chin-Wei Chang, Wei-Fan Hsu, Kuo-Chih Tseng, Chi-Yi Chen, Pin-Nan Cheng, Ching-Chu Lo, Wan-Long Chuang

Dig Dis Sci· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy.
Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Gin-Ho Lo, Ching-Chu Lo, Wan-Long Chung

Clin Mol Hepatol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.
Chun-Chi Yang, Chung-Feng Huang, Te-Sheng Chang, Ching-Chu Lo, Chao-Hung Hung, Wang-Long Chuang

Infect Dis Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.
Ming-Lung Yu, Chi-Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Chung-Feng Huang, Ching-Chu Lo, Wan-Long Chuang

Hepatol Int· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A therapeutic dose and its pharmacokinetics of ropeginterferon Alfa-2b for hepatitis C treatment.
Ching-Chu Lo, Wan-Long Chuang, Hsing-Tao Kuo, Wei-Ming Chen, Albert Qin

J Formos Med Assoc· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Ming-Ying Lu, Chung-Feng Huang, Chao-Hung Hung, Chi-Ming Tai, Lein-Ray Mo, Ching-Chu Lo, Wan-Long Chuang

Clin Mol Hepatol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan - A multi-center collaborative care model.
Ching-Chu Lo, Wei-Yi Lei, Ying-Che Huang, Jow-Jyh Hwang, Chen-Yu Lo

J Microbiol Immunol Infect· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Te-Sheng Chang, Chung-Feng Huang, Hsing-Tao Kuo, Ching-Chu Lo, Chien-Wei Huang, Wang-Long Chuang

Hepatol Int· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan.
Chen-Hua Liu, Cheng-Yuan Peng, Chun-Jen Liu, Chi-Yi Chen, Ching-Chu Lo

Hepatol Int· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
Pei-Chien Tsai, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Gin-Ho Lo, Ching-Chu Lo, Wan-Long Chung

J Hepatol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 3 clinical trial validating the potency and safety of an innovative, extra-long-acting interferon in chronic hepatitis C.
Chi-Yi Chen, Wan-Long Chuang, Albert Qin, Wen-Hua Zhang, Li-Ying Zhu, Ching-Chu Lo, Gin-Ho Lo

JGH Open· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Ching-Chu Lo, Chung-Feng Huang, Pin-Nan Cheng, Kuo-Chih Tseng, Chi-Yi Chen, Wan-Long Chuang

J Formos Med Assoc· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk stratification of hepatocellular carcinoma incidence using a fibrosis-4-based prediction model in patients with chronic hepatitis C receiving antiviral therapy: a nationwide real-world Taiwanese cohort study.
Hung-Wei Wang, Pei-Chein Tsai, Chi-Yi Chen, Kuo-Chih Tseng, Hsueh-Chou Lai, Gin-Ho Lo, Ching-Chu Lo, Wan-Long Chuang

Am J Cancer Res· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
Yen-Chun Chen, Te-Sheng Chang, Chien-Hung Chen, Pin-Nan Cheng, Ching-Chu Lo, Wan-Long Chuang

Viruses· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis